FDA gives emergency approval to use anti-malaria drugs to fight coronavirus
Agency action gives doctors more latitude to use chloroquine and hydroxychloroquine to treat COVID-19 patients.
The Facts Inside Our Reporter’s Notebook
The Food and Drug Administration on Sunday gave doctors emergency permission to use the anti-malarial drugs hydroxychloroquine and chloroquine to treat the coronavirus.
The agency's action allows the medicines "to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible," according to a Department of Health and Human Services statement.
"Although there are no currently approved treatments for COVID-19, both drugs have shown activity in laboratory studies against coronaviruses, including SARS-CoV-2 (the virus that causes COVID-19). Anecdotal reports suggest that these drugs may offer some benefit in the treatment of hospitalized COVID-19 patients. Clinical trials are needed to provide scientific evidence that these treatments are effective," HHS said in making the announcement.
Officials also announced that two drugmakers, Sandoz and Bayer, had donated 31 million doses of the two medicines to the government's emergency stockpile to be used by doctors.
Medical research dating to 2003 has suggested the two drugs might be helpful in fighting coronavirus symptoms, and President Trump as well as several foreign allies have promoted their use as a potential break-though. But the medical community never completed formal clinical trials, which only began in recent weeks and will take months to complete.
News, not Noise
- Effort to spread discredited Russia collusion theory welcomed by McCain Senate panel, memos show
- Draft report of Maricopa audit finds Biden won but flags as many as 44,000 votes as 'critical'
- White House tells agencies to begin preparing for potential government shutdown
- Ten questions the Arizona election audit could answer Friday
- DeSantis sidesteps Biden rationing, acquires new monoclonal antibodies from U.K. drug firm